MX2023008804A - Formulacion liquida de proteina, y metodos de preparacion de la misma. - Google Patents

Formulacion liquida de proteina, y metodos de preparacion de la misma.

Info

Publication number
MX2023008804A
MX2023008804A MX2023008804A MX2023008804A MX2023008804A MX 2023008804 A MX2023008804 A MX 2023008804A MX 2023008804 A MX2023008804 A MX 2023008804A MX 2023008804 A MX2023008804 A MX 2023008804A MX 2023008804 A MX2023008804 A MX 2023008804A
Authority
MX
Mexico
Prior art keywords
liquid formulation
protein
preparing
same
methods
Prior art date
Application number
MX2023008804A
Other languages
English (en)
Inventor
Hyung Kyu Lim
Sang Yun Kim
Sung Hee Hong
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2023008804A publication Critical patent/MX2023008804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se provee una formulación líquida de proteína y un método para preparar la misma; con base en una formulación líquida que contiene una alta concentración de eflapegrastim y un método para preparar la misma, la formulación líquida puede tener excelente solubilidad y estabilidad, puede tener una alta concentración de proteína, y puede ser inyectada de una manera favorable para el paciente debido a la reducción de la irritación/dolor en el sitio de administración o de la molestia en el paciente.
MX2023008804A 2021-01-27 2022-01-26 Formulacion liquida de proteina, y metodos de preparacion de la misma. MX2023008804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210011802A KR102375269B1 (ko) 2021-01-27 2021-01-27 단백질 액상 제제 및 이의 제조방법
PCT/KR2022/001406 WO2022164204A1 (en) 2021-01-27 2022-01-26 Liquid formulation of protein and methods of preparing the same

Publications (1)

Publication Number Publication Date
MX2023008804A true MX2023008804A (es) 2023-08-04

Family

ID=80936291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008804A MX2023008804A (es) 2021-01-27 2022-01-26 Formulacion liquida de proteina, y metodos de preparacion de la misma.

Country Status (12)

Country Link
US (1) US20240082355A1 (es)
EP (1) EP4284340A1 (es)
JP (1) JP2024505211A (es)
KR (1) KR102375269B1 (es)
CN (1) CN116782882A (es)
AR (1) AR124700A1 (es)
AU (1) AU2022213961A1 (es)
CA (1) CA3206349A1 (es)
IL (1) IL304528A (es)
MX (1) MX2023008804A (es)
TW (1) TW202231295A (es)
WO (1) WO2022164204A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
EP2525787B1 (en) * 2010-01-19 2017-03-15 Hanmi Science Co., Ltd. Liquid formulations for long-acting g-csf conjugate
WO2013173687A1 (en) * 2012-05-18 2013-11-21 Genentech, Inc. High-concentration monoclonal antibody formulations
BR112016025126B1 (pt) * 2014-05-07 2024-02-15 Takeda Pharmaceutical Company Limited Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
KR20200112881A (ko) * 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
JP2021512121A (ja) * 2018-02-01 2021-05-13 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Also Published As

Publication number Publication date
EP4284340A1 (en) 2023-12-06
AR124700A1 (es) 2023-04-26
AU2022213961A1 (en) 2023-08-10
TW202231295A (zh) 2022-08-16
CA3206349A1 (en) 2022-08-04
IL304528A (en) 2023-09-01
WO2022164204A1 (en) 2022-08-04
US20240082355A1 (en) 2024-03-14
CN116782882A (zh) 2023-09-19
KR102375269B1 (ko) 2022-03-17
JP2024505211A (ja) 2024-02-05

Similar Documents

Publication Publication Date Title
ATE537814T1 (de) Nanoliposom mit verestertem lecithin und herstellungsverfahren dafür und dieses enthaltende zusammensetzung zur prävention oder behandlung von hauterkrankungen
MX2023008804A (es) Formulacion liquida de proteina, y metodos de preparacion de la misma.
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
IS2384B (is) Notkun dókósahexensýru sem virks efnis til að meðhöndla fitukyrking
MX2021000037A (es) Nueva formulacion estable de alta concentracion para anticuerpos anti-fxia.
EA202092077A1 (ru) Местные составы, содержащие стронций и метилсульфонилметан (мсм), и способы лечения
CN104474577A (zh) 一种激光美容术后敷料及制备方法
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JP2021080255A (ja) 勃起不全治療用薬剤、その製造方法及び勃起不全治療用器具
US20160106798A1 (en) Topical treatment for use in conjunction with acupuncture or acupressure therapy
MD3803G2 (ro) Metodă de tratament al hiperchineziilor la copii
MX2021004463A (es) Terapia de disminución de arginina para el tratamiento de la deficiencia de gamt.
KR102629903B1 (ko) N-아세틸글루코사민 유도체를 유효성분으로 함유하는 주입용 필러 조성물
CN108143709A (zh) 促进第五型磷酸二酯酶抑制剂经皮吸收的方法及医药组合物
RU2527905C1 (ru) Способ лечения туберкулезного спастического микроцистиса
CA3056919A1 (en) Method of treatment of skin conditions of eye lids
MX2009004635A (es) Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
JP2004189676A (ja) 損傷皮膚改善用外用剤
AU2016100435A4 (en) Creation of a bespoke skin regeneration treatment utilising platelet rich plasma of individual patients mixed with an organic anti-oxidant emollient cream base which is applied ( after snap freezing with liquid nitrogen) immediately following( and for 72 hrs after at 3-6 hrly intervals) unique skin resurfacing and pigment treatment
Karki et al. A case of actinomycetoma treated with trimethoprim+ sulfamethoxazole
WO2023150579A3 (en) Pharmaceutical formulations containing nalbuphine
Walling Comments on ‘Inserting the etonogestrel contraceptive implant’: author's response
Zhong-fei et al. Perforator vascular anatomy and clinical application of the anteromedial thigh flap for head and neck reconstruction